‘Game-changing’ new Alzheimer’s drug could slow progression of disease

Alzheimer’s medicine which eliminates the accumulation of plaque in the brain Slow progression of the disease and delay the appearance of symptoms, The first trials showed.

There is currently no remedy the disease, which Can seriously affect memory and an impact on people’s ability to perform daily tasks, and available drugs can only reduce symptoms.

But a new medicine Called TrontineMab shows promising results, the international conference of the Alzheimer’s association in Toronto was said.

THE medicine Was tested on a small number of patients, but 49 out of 54 with Alzheimer’s at an early stage showed signs of improvement within 28 weeks during a trial, according to RockThe pharmaceutical company behind the medication.

The researchers said that 91% of participants showed a reduction in protein clusters on their brain, called amyloid plates – a key marker from Alzheimer.

Alzheimer’s is believed to be caused by an abnormal accumulation of this protein around brain cells, while another protein called tau forms tangles in brain cells.

These can interrupt the chemical messengers responsible for sending signals between brain cells, according to the NHS.

The new medication has proven to reduce amyloid proteins to such a low level that the scan results on patients who took it for seven months were considered “negative amyloid”.

It is believed that the clearance of plates slows the progression of the disease and delays the appearance of symptoms.

“Alzheimer’s disease represents one of the biggest health care challenges today, and this requires early detection and effective therapy,” said Dr. Levi Garraway, chief of chief Rock, said.

He added: “The TrontineMab is designed to more effectively target a key engine of the biology of Alzheimer’s disease in the brain. The combination of new treatment avenues with advanced diagnoses can allow intervention earlier and potentially more efficient.”

Professor Sir John Hardy, president of the molecular biology of neurological diseases at the Institute of Neurology of the University College of London, which was not involved in the trial, said The telegraph The drug was a “massive improvement” and operates faster than other Alzheimer’s drugs on the market.

“There is no doubt that this could change the situation. We hope that if we can use these drugs for people early, we can stop the progress of the disease, even before people have symptoms. We must now see the size of the clinical effect,” he said.

However, the drug has side effects, with five participants of 149 (3%) suffering from lesions or swelling in their brain after having taken it. But all the participants recovered, and it was considered safer than the other Alzheimer’s drugs which resulted in 17% of participants with similar side effects.

The last part of the trial, which will test the medication on a large number of patients, has not yet been carried out. But if he succeeds, health organizations in the United Kingdom will have to decide if it is profitable enough to use on the NHS.

It is estimated that 982,000 people live with a form of dementia, including Alzheimer’s disease in the United Kingdom, with the most frequent disease in people over 65.

But more than a third of people with the disease have no diagnosis. The number of people with disease should reach 1.4 million by 2040, according to Alzheimer’s company.